134 related articles for article (PubMed ID: 36447041)
1. Healthcare Resource Utilization and Associated Costs of German Patients with Diffuse Large B-Cell Lymphoma: A Retrospective Health Claims Data Analysis.
Borchmann P; Heger JM; Mahlich J; Papadimitrious MS; Riou S; Werner B
Oncol Ther; 2023 Mar; 11(1):65-81. PubMed ID: 36447041
[TBL] [Abstract][Full Text] [Related]
2. Survival outcomes of patients newly diagnosed with diffuse large B-cell lymphoma: real-world evidence from a German claims database.
Borchmann P; Heger JM; Mahlich J; Papadimitrious MS; Riou S; Werner B
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7091-7101. PubMed ID: 36871091
[TBL] [Abstract][Full Text] [Related]
3. Economic burden and treatment patterns for patients with diffuse large B-cell lymphoma and follicular lymphoma in the USA.
Ren J; Asche CV; Shou Y; Galaznik A
J Comp Eff Res; 2019 Apr; 8(6):393-402. PubMed ID: 30855175
[TBL] [Abstract][Full Text] [Related]
4. Real-World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B-Cell Lymphoma in the U.S.
Yang X; Laliberté F; Germain G; Raut M; Duh MS; Sen SS; Lejeune D; Desai K; Armand P
Oncologist; 2021 May; 26(5):e817-e826. PubMed ID: 33616256
[TBL] [Abstract][Full Text] [Related]
5. A Real-World Claims Analysis of Costs and Patterns of Care in Treated Patients with Glioblastoma Multiforme in the United States.
Norden AD; Korytowsky B; You M; Kim Le T; Dastani H; Bobiak S; Singh P
J Manag Care Spec Pharm; 2019 Apr; 25(4):428-436. PubMed ID: 30917077
[TBL] [Abstract][Full Text] [Related]
6. Health resource utilization and costs of care for adult patients with relapsed or refractory mantle cell lymphoma in the United States: a retrospective claims analysis.
Ito D; Feng C; Fu C; Kim C; Wu J; Epstein J; Snider JT; DuVall AS
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):773-787. PubMed ID: 37278284
[TBL] [Abstract][Full Text] [Related]
7. Direct Costs Associated with Relapsed Diffuse Large B-Cell Lymphoma Therapies.
Purdum A; Tieu R; Reddy SR; Broder MS
Oncologist; 2019 Sep; 24(9):1229-1236. PubMed ID: 30850561
[TBL] [Abstract][Full Text] [Related]
8. Health care resource utilization and costs among patients with multiple myeloma with exposure to double-class or triple-class multiple myeloma treatments: A retrospective US claims database analysis.
Yang J; Boytsov N; Carlson JJ; Barthold D
J Manag Care Spec Pharm; 2023 Aug; 29(8):917-926. PubMed ID: 37523320
[No Abstract] [Full Text] [Related]
9. Healthcare resource utilization and associated costs in patients with metastatic urothelial carcinoma: a real-world analysis using German claims data.
Niegisch G; Grimm MO; Hardtstock F; Krieger J; Starry A; Osowski U; Deiters B; Maywald U; Wilke T; Kearney M
J Med Econ; 2024; 27(1):531-542. PubMed ID: 38639988
[TBL] [Abstract][Full Text] [Related]
10. Nationwide claims database analysis of treatment patterns, costs and survival of Japanese patients with diffuse large B-cell lymphoma.
Tsutsué S; Tobinai K; Yi J; Crawford B
PLoS One; 2020; 15(8):e0237509. PubMed ID: 32810157
[TBL] [Abstract][Full Text] [Related]
11. Economic burden in patients with ALK + non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors.
Lin HM; Pan X; Hou P; Huang H; Wu Y; Ren K; Jahanzeb M
J Med Econ; 2020 Aug; 23(8):894-901. PubMed ID: 32347754
[No Abstract] [Full Text] [Related]
12. A nationwide analysis of the treatment patterns, survival, and medical costs in Korean patients with relapsed or refractory diffuse large B-cell lymphoma.
Cho JY; Jang SC; Kang DW; Lee EK; Koh H; Yoon DH; Park MH
Front Oncol; 2024; 14():1282323. PubMed ID: 38361777
[TBL] [Abstract][Full Text] [Related]
13. Healthcare Resource Utilization and Cost of Patients with Multiple Myeloma in Germany: A Retrospective Claims Data Analysis.
Kocaata Z; Wilke T; Fischer F; Welte R; Einsele H
Pharmacoecon Open; 2022 Jul; 6(4):619-628. PubMed ID: 35750956
[TBL] [Abstract][Full Text] [Related]
14. Inpatient treatment of relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): A health economic perspective.
Moertl B; Dreyling M; Schmidt C; Hoster E; Schoel W; Bergwelt-Baildon MV; Berger K
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):474-482. PubMed ID: 35033478
[TBL] [Abstract][Full Text] [Related]
15. Epidemiology and Real-World Treatment of Incident Diffuse Large B-cell Lymphoma (DLBCL): A German Claims Data Analysis.
Pacis S; Bolzani A; Heuck A; Gossens K; Kruse M; Fritz B; Maywald U; Wilke T; Kunz C
Oncol Ther; 2024 Feb; ():. PubMed ID: 38379108
[TBL] [Abstract][Full Text] [Related]
16. Incidence, economic burden, and treatment of acute respiratory tract infection in hematopoietic stem cell transplantation recipients using real world data in Japan: a retrospective claims data analysis.
Wattanakamolkul K; Nakayama Y
J Med Econ; 2022; 25(1):870-879. PubMed ID: 35703058
[TBL] [Abstract][Full Text] [Related]
17. Treatment patterns, adverse events, healthcare resource use and costs among commercially insured patients with mantle cell lymphoma in the United States.
Kabadi SM; Near A; Wada K; Burudpakdee C
Cancer Med; 2019 Dec; 8(17):7174-7185. PubMed ID: 31595715
[TBL] [Abstract][Full Text] [Related]
18. Health Care Resource Utilization and Costs for Patients with Spinal Muscular Atrophy: Findings from a Retrospective US Claims Database Analysis.
Toro W; Yang M; Georgieva M; Song W; Patel A; Jiang AX; Zhao A; LaMarca N; Dabbous O
Adv Ther; 2023 Oct; 40(10):4589-4605. PubMed ID: 37587305
[TBL] [Abstract][Full Text] [Related]
19. Treatment patterns, healthcare resource utilization, and costs of patients diagnosed with primary mediastinal B-cell lymphoma in the United States.
Yang X; Laliberté F; Germain G; Raut M; Duh MS; Sen SS; Lejeune D; Desai K; Armand P
J Med Econ; 2021; 24(1):469-478. PubMed ID: 33784916
[TBL] [Abstract][Full Text] [Related]
20. Burden of Illness and Treatment Patterns in Second-line Large B-cell Lymphoma.
Snider JT; McMorrow D; Song X; Diakun D; Wade SW; Cheng P
Clin Ther; 2022 Apr; 44(4):521-538. PubMed ID: 35241295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]